ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Zydus gets DCGI approval to commence Phase III clinical trials with Pegylated Interferon alpha-2b
December 07, 2020In Phase II clinical trials, Pegylated Interferon alpha – 2b increased viral reduction and reduced the need for supplemental oxygen in moderate COVID-19 patients. -
Zydus concludes Phase II trials of Pegylated Interferon alpha-2b for COVID-19, to begin Phase III trials
November 13, 2020In 19 out of 20 patients, a single 1 mcg/kg dose of the drug demonstrated viral clearance as assessed by RT-PCR and a significant improvement in clinical symptoms, informs the company.
Pharma Sources Insight January 2025
